Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
New England Journal of Medicine2025Vol. 392(18), pp. 1813–1823
Citations Over TimeTop 1% of 2025 papers
Luke J. Laffin, Branko Kopjar, Carrie Melgaard, Kathy Wolski, Jessica Ibbitson, Shivani Bhikam, Matthew R. Weir, Elizabeth Ofili, Reena Mehra, James M. Luther, Debbie L. Cohen, Ashish Sarraju, M. J. Wilkinson, John M. Flack, David Rodman, Steven E. Nissen
Abstract
Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo in participants with uncontrolled and treatment-resistant hypertension. (Funded by Mineralys Therapeutics; Advance-HTN ClinicalTrials.gov number, NCT05769608.).
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)